| Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 R Lozano, M Naghavi, K Foreman, S Lim, K Shibuya, V Aboyans, ... The lancet 380 (9859), 2095-2128, 2012 | 18804 | 2012 |
| Genetics of rheumatoid arthritis contributes to biology and drug discovery Y Okada, D Wu, G Trynka, T Raj, C Terao, K Ikari, Y Kochi, K Ohmura, ... Nature 506 (7488), 376-381, 2014 | 2627 | 2014 |
| Pharmacogenetics: from bench to byte—an update of guidelines JJ Swen, M Nijenhuis, A de Boer, L Grandia, AH Maitland‐van der Zee, ... Clinical Pharmacology & Therapeutics 89 (5), 662-673, 2011 | 1267 | 2011 |
| Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions A Vermes, HJ Guchelaar, J Dankert Journal of Antimicrobial Chemotherapy 46 (2), 171-179, 2000 | 963 | 2000 |
| The risk of cancer in users of statins MR Graaf, AB Beiderbeck, ACG Egberts, DJ Richel, HJ Guchelaar Journal of clinical oncology 22 (12), 2388-2394, 2004 | 630 | 2004 |
| Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition C Braegger, A Chmielewska, T Decsi, S Kolacek, W Mihatsch, L Moreno, ... Journal of pediatric gastroenterology and nutrition 52 (2), 238-250, 2011 | 586 | 2011 |
| Cardiotoxicity of cytotoxic drugs KJM Schimmel, DJ Richel, RBA Van den Brink, HJ Guchelaar Cancer treatment reviews 30 (2), 181-191, 2004 | 575 | 2004 |
| Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and … KE Caudle, K Sangkuhl, M Whirl‐Carrillo, JJ Swen, CE Haidar, TE Klein, ... Clinical and translational science 13 (1), 116-124, 2020 | 490 | 2020 |
| Clinical pharmacokinetics of tyrosine kinase inhibitors NP van Erp, H Gelderblom, HJ Guchelaar Cancer treatment reviews 35 (8), 692-706, 2009 | 487 | 2009 |
| Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis JAM Wessels, TWJ Huizinga, HJ Guchelaar Rheumatology 47 (3), 249-255, 2008 | 433 | 2008 |
| DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ... The Lancet Oncology 19 (11), 1459-1467, 2018 | 427 | 2018 |
| Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer MR Graaf, DJ Richel, CJF van Noorden, HJ Guchelaar Cancer treatment reviews 30 (7), 609-641, 2004 | 374 | 2004 |
| Making sense of big data in health research: towards an EU action plan C Auffray, R Balling, I Barroso, L Bencze, M Benson, J Bergeron, ... Genome medicine 8, 1-13, 2016 | 358 | 2016 |
| A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ... The Lancet 401 (10374), 347-356, 2023 | 337 | 2023 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy MP Goetz, K Sangkuhl, HJ Guchelaar, M Schwab, M Province, ... Clinical Pharmacology & Therapeutics 103 (5), 770-777, 2018 | 337 | 2018 |
| Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium CH van der Wouden, A Cambon‐Thomsen, E Cecchin, KC Cheung, ... Clinical Pharmacology & Therapeutics 101 (3), 341-358, 2017 | 330 | 2017 |
| Liposomal drug formulations in cancer therapy: 15 years along the road M Slingerland, HJ Guchelaar, H Gelderblom Drug discovery today 17 (3-4), 160-166, 2012 | 323 | 2012 |
| A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent‐onset rheumatoid arthritis JAM Wessels, SM van der Kooij, S le Cessie, W Kievit, P Barerra, ... Arthritis & Rheumatism 56 (6), 1765-1775, 2007 | 310 | 2007 |
| Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single‐nucleotide polymorphisms in genes coding for folate pathway enzymes JAM Wessels, JK de Vries‐Bouwstra, BT Heijmans, PE Slagboom, ... Arthritis & Rheumatism 54 (4), 1087-1095, 2006 | 304 | 2006 |
| Pharmacogenetics: from bench to byte JJ Swen, I Wilting, AL De Goede, L Grandia, H Mulder, DJ Touw, ... Clinical pharmacology & therapeutics 83 (5), 781-787, 2008 | 302 | 2008 |
